Imase Kyoto, Tanaka Akifumi, Tokunaga Kengo, Sugano Hajime, Ishida Hitoshi, Takahashi Shin'ichi
Third Department of Internal Medicine, Kyorin University School of Medicine, 16-20-2 Shinkawa, Mitaka-shi, Tokyo 181-8611, Japan.
Kansenshogaku Zasshi. 2007 Jul;81(4):387-93. doi: 10.11150/kansenshogakuzasshi1970.81.387.
We studied the effect of Lactobacillus reuteri strain SD2112 Tablets Reuterina (ERINA Co., Inc.), in suppressing H. pylori urease activity and to use the urea breath test (UBT) as a marker for the burden of infection. Method 1: Assessment of UBT and H. pylori density. Subjects were 33 H. pylori-positive patients from whom were obtained gastric biopsy specimens by upper gastrointestinal endoscopy. The correlation between UBT and H. pylori density was investigated. Individual UBT was established for each patient. Patients were divided by H. pylori density was 3 groups: Group I (low-density), Group II (moderate-density), and Group III (high-density). The individual UBTs were then correlated to the established H. pylori quantity. Method 2: Assessment of suppressive effect of L. reuteri on H. pylori urease activity. Subjects were 40 asymptomatic volunteers with an UBT exceeding 15 per thousand, randomly allocated to four groups: Subjects in Group A underwent active treatment for 4 weeks (period 1) and placebo treatment for the following 4 weeks (period 2). These in Group B underwent treatment in reverse order. Those in Group C underwent placebo. Group D consisted of volunteers with negative UBT undergoing active treatment for the full 8 weeks. Result 1: UBT was 11.6+/-2.0 per thousand, 22.1+/-2.6 per thousand, and 35.4+/-7.6 per thousand in Groups I, II, and III, showing UBT that increased significantly (I vs. II: p< 0.01 and I vs. III: p<0.05) based on H. pylori density. Result 2:Significant differences were seen in the decrease in UBT before versus after medication in Groups A and B. In Group A, lower UBT was maintained until the end of the full 8-week period. The overall decrease in UBT due to medication with L. reuteri Tablets was 69.7+/-4.0% (p<0.05).
Administration of L. reuteri Tablets [Reuterina (ERINA Co.,Inc.)] significantly decreased UBT in H. pylori-positive subjects, demonstrating that L. reuteri suppresses H. pylori urease activity and H. pylori density.
我们研究了罗伊氏乳杆菌菌株SD2112片剂(Reuterina,ERINA公司)对抑制幽门螺杆菌脲酶活性的作用,并将尿素呼气试验(UBT)用作感染负担的标志物。方法1:UBT和幽门螺杆菌密度的评估。受试者为33例幽门螺杆菌阳性患者,通过上消化道内镜检查获取胃活检标本。研究了UBT与幽门螺杆菌密度之间的相关性。为每位患者建立个体UBT。根据幽门螺杆菌密度将患者分为3组:I组(低密度)、II组(中度密度)和III组(高密度)。然后将个体UBT与既定的幽门螺杆菌数量相关联。方法2:罗伊氏乳杆菌对幽门螺杆菌脲酶活性抑制作用的评估。受试者为40名无症状志愿者,其UBT超过千分之15,随机分为四组:A组受试者接受4周的积极治疗(第1阶段),随后4周接受安慰剂治疗(第2阶段)。B组受试者按相反顺序接受治疗。C组受试者接受安慰剂治疗。D组由UBT阴性的志愿者组成,他们在整个8周内接受积极治疗。结果1:I组、II组和III组的UBT分别为千分之11.6±2.0、千分之22.1±2.6和千分之35.4±7.6,表明基于幽门螺杆菌密度,UBT显著增加(I组与II组:p<0.01,I组与III组:p<0.05)。结果2:A组和B组用药前后UBT的下降存在显著差异。在A组中,较低的UBT一直维持到整个8周结束。罗伊氏乳杆菌片剂用药导致的UBT总体下降为69.7±4.0%(p<0.05)。
服用罗伊氏乳杆菌片剂[Reuterina(ERINA公司)]可显著降低幽门螺杆菌阳性受试者的UBT,表明罗伊氏乳杆菌可抑制幽门螺杆菌脲酶活性和幽门螺杆菌密度。